Human cytomegalovirus virion envelope glycoprotein complex

The "CMV virion surface proteins" refers primarily to the various viral envelope glycoprotein complexes that protrude from the lipid membrane of the human cytomegalovirus (HCMV) virion. The envelope contains several major glycoprotein complexes, most notably gB (glycoprotein B, encoded by UL55), gH/gL (glycoprotein H/glycoprotein L, encoded by UL75/UL115), gM/gN (glycoprotein M/glycoprotein N, encoded by UL100/UL73), and the pentameric complex (gH/gL/UL128-131a) crucial for infection of epithelial and endothelial cells[2][4][10]. These proteins are essential for viral entry into host cells, cell tropism, and are major targets of the host immune response[2][4]. They are critical both for binding to cellular receptors and for mediating the membrane fusion process necessary for infection. As structural antigens, they serve as primary targets for vaccine development and neutralizing antibody therapies, though no small-molecule drugs in current clinical use directly target them. Notably, the query "CMV virion surface proteins" is not sufficiently specific—it is a collective term rather than a precise molecular target and encompasses multiple distinct protein complexes. For structured applications, it is preferable to assign canonical names to individual glycoproteins (e.g., "Human cytomegalovirus glycoprotein B") rather than to all envelope glycoproteins collectively[4][10].

Other names

CMV virion glycoproteinsCMV envelope glycoprotein complexesHCMV envelope proteinsHCMV glycoproteins (e.g., gB, gH/gL, gM/gN, gO, gL, gN, gM, gB)

Antibodies targeting glycoproteins can neutralize viral entry by blocking receptor engagement or membrane fusion[2][4][10] Inhibitors of glycoprotein-mediated fusion are under development Antiviral drugs used clinically do not primarily target envelope glycoproteins, but vaccines and monoclonal antibodies aim to neutralize these proteins